Oncotarget

Vol 14 (2023)

View Archive »

Table of Contents

Research Papers

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001

https://doi.org/10.18632/oncotarget.28341

Xiaofan Li, Cristina Abrahams, Abigail Yu, Millicent Embry, Robert Henningsen, Venita DeAlmeida, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Trevor Hallam, Mark Lupher,  and Arturo Molina
1-13
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release

Research Papers

Candidate drugs associated with sensitivity of cancer cell lines with DLST amplification or high mRNA levels

Candidate drugs associated with sensitivity of cancer cell lines with DLST amplification or high mRNA levels

https://doi.org/10.18632/oncotarget.28342

Christina Kuhn, Myriam Boeschen, Manuel Philip, Torsten Schöneberg, Doreen Thor,  and Susanne Horn
14-20
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Corrections

Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma

Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma

https://doi.org/10.18632/oncotarget.28336

David King, Xiao Dun Li, Gilberto S. Almeida, Colin Kwok, Polly Gravells, Daniel Harrison, Saoirse Burke, Albert Hallsworth, Yann Jamin, Sally George, Simon P. Robinson, Christopher J. Lord, Evon Poon, Daniel Yeomanson, Louis Chesler,  and Helen E. Bryant
21-22
Correction  |  PDF  |  How to cite

Research Papers

The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option

The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option

https://doi.org/10.18632/oncotarget.28338

Jessica T. Gomes, Ana Márcia V. Wanzeler, Sergio M.A. Júnior, Rosa Helena F. Chaves Soares, Carolina P. de Oliveira, Emanuelle de M. Rodrigues, Bruno M. Soares, Diego D.F.A. Alcantara, Rommel M.R. Burbano,  and Fabrício M. Tuji
23-39
Abstract  |  PDF  |  Full Text  |  How to cite  |  Press Release

Research Perspectives

Intraventricular immunovirotherapy; a translational step forward

Intraventricular immunovirotherapy; a translational step forward

https://doi.org/10.18632/oncotarget.28343

Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang,  and Gregory K. Friedman
40-43
Abstract  |  PDF  |  Full Text  |  How to cite  |  Press Release

Corrections

Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells

Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells

https://doi.org/10.18632/oncotarget.28344

Rehanna Mansor, Jeff Holly, Rachel Barker, Kalina Biernacka, Hanna Zielinska, Anthony Koupparis, Edward Rowe, Jon Oxley, Alex Sewell, Richard M. Martin, Athene Lane, Lucy Hackshaw-McGeagh,  and Claire Perks
44-46
Correction  |  PDF  |  How to cite

Editorial

To be or not to be: the role of CD56 in multiple myeloma

To be or not to be: the role of CD56 in multiple myeloma

https://doi.org/10.18632/oncotarget.28350

Francesca Cottini,  and Don Benson
47-49
PDF  |  How to cite

Retraction

Retraction: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met

Retraction: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met

https://doi.org/10.18632/oncotarget.28329

Chengcao Sun, Ming Sang, Shujun Li, Xiaodong Sun, Cuili Yang, Yongyong Xi, Liang Wang, Feng Zhang, Yongyi Bi, Yunfeng Fu,  and Dejia Li
50-50
Retraction  |  PDF  |  How to cite

Editorial

Permeability and driving force: why is difficult to control glycolytic flux by blocking lactate transporters?

Permeability and driving force: why is difficult to control glycolytic flux by blocking lactate transporters?

https://doi.org/10.18632/oncotarget.28351

Wiktoria Blaszczak,  and Pawel Swietach
51-52
PDF  |  How to cite

Corrections

Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

https://doi.org/10.18632/oncotarget.28345

Fiorella Vanderhoeven, Analía Lourdes Redondo, Ana Laura Martinez, Laura María Vargas-Roig, Angel Matias Sanchez,  and Marina Inés Flamini
53-53
Correction  |  PDF  |  How to cite

Editorial

The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system

The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system

https://doi.org/10.18632/oncotarget.28349

Munemasa Nagao, Akihisa Fukuda,  and Hiroshi Seno
54-56
PDF  |  How to cite

Research Papers

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)

https://doi.org/10.18632/oncotarget.28352

Leo I. Gordon, Reem Karmali, Jason B. Kaplan, Rakesh Popat, Howard A. Burris III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, F. Ian Chau, John Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan P. Iyer, William Townsend, Harry Miao, Igor Proscurshim, Shining Wang, Shilpi Katyayan, Ying Yuan, Jiaxi Zhu, Kate Stumpo, Yaping Shou, Cecilia Carpio,  and Francesc Bosch
57-70
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Press Release

Research Papers

Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer

Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer

https://doi.org/10.18632/oncotarget.28353

Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Yohei Sasaki, Koki Kawakami, Ryoji Hyakudomi, Tetsu Yamamoto,  and Yoshitsugu Tajima
71-82
Abstract  |  PDF  |  Full Text  |  How to cite

Corrections

Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6

Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6

https://doi.org/10.18632/oncotarget.28115

Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, Stefanie Krassnig, Margit Gogg-Kamerer, Nadine Gantenbein, Anna M. Toeglhofer, Christina Wodlej, Helmut Bergler, Brigitte Pertschy, Stefan Uranitsch, Magdalena Holter, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Henderson, Hans Lehrach, Christoph Reinhard, Christian Regenbrecht, Rudolf Schicho, Peter Fickert, Sigurd Lax,  and Johannes Haybaeck
83-84
Correction  |  PDF  |  How to cite

Research Papers

Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)

Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)

https://doi.org/10.18632/oncotarget.28355

Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal,  and Cherie-Ann O. Nathan
85-95
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Research Perspectives

The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

https://doi.org/10.18632/oncotarget.28354

Anqi Shao,  and David M. Owens
96-103
Abstract  |  PDF  |  Full Text  |  How to cite


Copyright © 2023 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC